Concepts (167)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Chest Pain | 3 | 2020 | 197 | 0.930 |
Why?
|
| Mortality | 2 | 2020 | 126 | 0.860 |
Why?
|
| Genital Neoplasms, Female | 6 | 2017 | 15 | 0.810 |
Why?
|
| Acute Coronary Syndrome | 2 | 2020 | 189 | 0.800 |
Why?
|
| Hospitalization | 2 | 2020 | 465 | 0.740 |
Why?
|
| Myocardial Infarction | 3 | 2020 | 469 | 0.730 |
Why?
|
| Ethnic Groups | 1 | 2020 | 480 | 0.610 |
Why?
|
| Troponin | 4 | 2020 | 99 | 0.560 |
Why?
|
| Deglutition Disorders | 2 | 2014 | 50 | 0.560 |
Why?
|
| Models, Statistical | 1 | 2014 | 176 | 0.450 |
Why?
|
| Gynecologic Surgical Procedures | 3 | 2017 | 46 | 0.400 |
Why?
|
| Head and Neck Neoplasms | 4 | 2014 | 129 | 0.400 |
Why?
|
| Treatment Outcome | 7 | 2017 | 3358 | 0.380 |
Why?
|
| Middle Aged | 22 | 2020 | 11949 | 0.340 |
Why?
|
| Adult | 19 | 2020 | 9467 | 0.330 |
Why?
|
| Neoplasms, Germ Cell and Embryonal | 2 | 2018 | 12 | 0.320 |
Why?
|
| Emergency Medical Services | 2 | 2020 | 165 | 0.300 |
Why?
|
| Aged | 17 | 2020 | 10398 | 0.290 |
Why?
|
| Postoperative Complications | 3 | 2017 | 788 | 0.280 |
Why?
|
| North Carolina | 6 | 2020 | 1520 | 0.270 |
Why?
|
| Tamoxifen | 2 | 2017 | 56 | 0.270 |
Why?
|
| Humans | 27 | 2020 | 32297 | 0.260 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 3 | 2020 | 462 | 0.260 |
Why?
|
| Odds Ratio | 4 | 2020 | 480 | 0.260 |
Why?
|
| Female | 21 | 2020 | 20126 | 0.250 |
Why?
|
| Logistic Models | 4 | 2020 | 788 | 0.240 |
Why?
|
| Quality of Life | 4 | 2016 | 915 | 0.210 |
Why?
|
| Male | 15 | 2020 | 19488 | 0.200 |
Why?
|
| Emergency Service, Hospital | 3 | 2020 | 463 | 0.200 |
Why?
|
| Carcinoma, Squamous Cell | 2 | 2014 | 154 | 0.190 |
Why?
|
| Young Adult | 9 | 2020 | 2626 | 0.190 |
Why?
|
| Testicular Neoplasms | 1 | 2020 | 19 | 0.180 |
Why?
|
| Teratoma | 1 | 2020 | 10 | 0.180 |
Why?
|
| Ambulances | 1 | 2020 | 14 | 0.180 |
Why?
|
| Naloxone | 1 | 2020 | 28 | 0.180 |
Why?
|
| Transportation of Patients | 1 | 2020 | 26 | 0.180 |
Why?
|
| Narcotic Antagonists | 1 | 2020 | 59 | 0.170 |
Why?
|
| Preventive Health Services | 1 | 2020 | 44 | 0.170 |
Why?
|
| Medical Oncology | 2 | 2018 | 84 | 0.170 |
Why?
|
| Decision Support Techniques | 1 | 2020 | 128 | 0.170 |
Why?
|
| Lymph Nodes | 1 | 2020 | 106 | 0.170 |
Why?
|
| Early Detection of Cancer | 1 | 2020 | 87 | 0.160 |
Why?
|
| Neoplasms, Second Primary | 1 | 2018 | 17 | 0.160 |
Why?
|
| Sex Factors | 1 | 2020 | 674 | 0.160 |
Why?
|
| Neoplasms | 2 | 2016 | 695 | 0.160 |
Why?
|
| Electronic Health Records | 1 | 2020 | 158 | 0.160 |
Why?
|
| Retrospective Studies | 8 | 2020 | 3514 | 0.150 |
Why?
|
| Patient Satisfaction | 2 | 2016 | 245 | 0.150 |
Why?
|
| Cystadenocarcinoma, Papillary | 1 | 2017 | 1 | 0.150 |
Why?
|
| Cystadenocarcinoma, Serous | 1 | 2017 | 3 | 0.150 |
Why?
|
| Estrogen Antagonists | 1 | 2017 | 16 | 0.140 |
Why?
|
| Analgesics, Opioid | 1 | 2020 | 262 | 0.140 |
Why?
|
| Uterine Neoplasms | 1 | 2017 | 27 | 0.140 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p16 | 1 | 2016 | 20 | 0.140 |
Why?
|
| T-Lymphocyte Subsets | 1 | 2016 | 26 | 0.140 |
Why?
|
| Cohort Studies | 6 | 2017 | 1832 | 0.140 |
Why?
|
| Esophagectomy | 1 | 2015 | 15 | 0.130 |
Why?
|
| Esophagogastric Junction | 1 | 2015 | 7 | 0.130 |
Why?
|
| European Continental Ancestry Group | 1 | 2020 | 1180 | 0.130 |
Why?
|
| Cytochrome P-450 CYP2D6 | 1 | 2015 | 1 | 0.130 |
Why?
|
| Esophageal Neoplasms | 1 | 2015 | 35 | 0.130 |
Why?
|
| Antineoplastic Agents, Hormonal | 1 | 2015 | 40 | 0.130 |
Why?
|
| Gastrectomy | 1 | 2015 | 67 | 0.130 |
Why?
|
| Risk Assessment | 5 | 2020 | 1447 | 0.130 |
Why?
|
| Stomach Neoplasms | 1 | 2015 | 84 | 0.130 |
Why?
|
| Prospective Studies | 5 | 2020 | 2274 | 0.130 |
Why?
|
| Upper Extremity Deep Vein Thrombosis | 1 | 2015 | 7 | 0.130 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2016 | 262 | 0.130 |
Why?
|
| Alleles | 1 | 2015 | 252 | 0.120 |
Why?
|
| Anxiety | 1 | 2016 | 185 | 0.120 |
Why?
|
| Adolescent | 6 | 2020 | 3571 | 0.120 |
Why?
|
| Stem Cell Transplantation | 1 | 2016 | 210 | 0.120 |
Why?
|
| Catheterization, Central Venous | 1 | 2015 | 63 | 0.120 |
Why?
|
| Preoperative Period | 1 | 2014 | 35 | 0.120 |
Why?
|
| Lymphoma | 1 | 2014 | 35 | 0.120 |
Why?
|
| Hispanic Americans | 1 | 2020 | 949 | 0.120 |
Why?
|
| Gastrointestinal Neoplasms | 1 | 2014 | 33 | 0.120 |
Why?
|
| Health Services | 1 | 2014 | 39 | 0.120 |
Why?
|
| Religion and Medicine | 1 | 2013 | 19 | 0.110 |
Why?
|
| Microfluidic Analytical Techniques | 1 | 2013 | 12 | 0.110 |
Why?
|
| Esophageal Stenosis | 1 | 2013 | 6 | 0.110 |
Why?
|
| Dilatation | 1 | 2013 | 8 | 0.110 |
Why?
|
| Neoplastic Cells, Circulating | 1 | 2013 | 23 | 0.110 |
Why?
|
| Esophagoscopy | 1 | 2013 | 19 | 0.110 |
Why?
|
| Computer Simulation | 1 | 2014 | 220 | 0.110 |
Why?
|
| African Americans | 1 | 2020 | 1443 | 0.110 |
Why?
|
| Aged, 80 and over | 6 | 2017 | 4050 | 0.110 |
Why?
|
| Cell Separation | 1 | 2013 | 94 | 0.110 |
Why?
|
| Papillomavirus Vaccines | 1 | 2013 | 44 | 0.110 |
Why?
|
| Follow-Up Studies | 5 | 2020 | 2296 | 0.110 |
Why?
|
| Survivors | 1 | 2014 | 157 | 0.110 |
Why?
|
| Cardiovascular Diseases | 1 | 2020 | 1133 | 0.100 |
Why?
|
| Parents | 1 | 2013 | 150 | 0.100 |
Why?
|
| Attitude to Health | 1 | 2013 | 167 | 0.100 |
Why?
|
| Time Factors | 4 | 2020 | 2181 | 0.100 |
Why?
|
| Pancreatic Neoplasms | 1 | 2013 | 142 | 0.100 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2013 | 171 | 0.100 |
Why?
|
| Decision Making | 1 | 2013 | 205 | 0.100 |
Why?
|
| Deglutition | 1 | 2011 | 29 | 0.100 |
Why?
|
| Neoadjuvant Therapy | 1 | 2011 | 67 | 0.100 |
Why?
|
| Breast Neoplasms | 1 | 2017 | 759 | 0.090 |
Why?
|
| Multivariate Analysis | 3 | 2017 | 696 | 0.080 |
Why?
|
| Risk Factors | 4 | 2020 | 3876 | 0.080 |
Why?
|
| Sensitivity and Specificity | 2 | 2020 | 600 | 0.080 |
Why?
|
| Predictive Value of Tests | 2 | 2020 | 877 | 0.080 |
Why?
|
| Obesity | 1 | 2014 | 1164 | 0.070 |
Why?
|
| Proportional Hazards Models | 2 | 2020 | 759 | 0.070 |
Why?
|
| Postoperative Period | 2 | 2016 | 100 | 0.070 |
Why?
|
| Longitudinal Studies | 2 | 2016 | 786 | 0.060 |
Why?
|
| Prognosis | 2 | 2020 | 1523 | 0.060 |
Why?
|
| Phenotype | 2 | 2015 | 656 | 0.050 |
Why?
|
| United States | 2 | 2020 | 3983 | 0.050 |
Why?
|
| Child | 2 | 2020 | 2472 | 0.050 |
Why?
|
| Cross-Sectional Studies | 2 | 2016 | 1522 | 0.050 |
Why?
|
| Point-of-Care Systems | 1 | 2020 | 45 | 0.050 |
Why?
|
| Orchiectomy | 1 | 2020 | 12 | 0.050 |
Why?
|
| Bleomycin | 1 | 2020 | 10 | 0.050 |
Why?
|
| Etoposide | 1 | 2020 | 34 | 0.050 |
Why?
|
| Retroperitoneal Space | 1 | 2020 | 21 | 0.040 |
Why?
|
| Life Support Care | 1 | 2020 | 16 | 0.040 |
Why?
|
| Eligibility Determination | 1 | 2020 | 17 | 0.040 |
Why?
|
| Cisplatin | 1 | 2020 | 77 | 0.040 |
Why?
|
| History, 21st Century | 1 | 2020 | 61 | 0.040 |
Why?
|
| Acute Disease | 1 | 2020 | 255 | 0.040 |
Why?
|
| Lymphatic Metastasis | 1 | 2020 | 172 | 0.040 |
Why?
|
| Lymph Node Excision | 1 | 2020 | 92 | 0.040 |
Why?
|
| Neoplasm Metastasis | 1 | 2020 | 222 | 0.040 |
Why?
|
| Diagnosis, Differential | 1 | 2020 | 525 | 0.040 |
Why?
|
| Medicare | 1 | 2020 | 206 | 0.040 |
Why?
|
| Infant, Newborn | 1 | 2020 | 681 | 0.040 |
Why?
|
| Women's Health Services | 1 | 2016 | 11 | 0.030 |
Why?
|
| Immunologic Memory | 1 | 2016 | 33 | 0.030 |
Why?
|
| Infant | 1 | 2020 | 1076 | 0.030 |
Why?
|
| Cluster Analysis | 1 | 2016 | 131 | 0.030 |
Why?
|
| Disease-Free Survival | 1 | 2017 | 320 | 0.030 |
Why?
|
| Quality of Health Care | 1 | 2017 | 151 | 0.030 |
Why?
|
| Child, Preschool | 1 | 2020 | 1281 | 0.030 |
Why?
|
| Lung Neoplasms | 1 | 2020 | 409 | 0.030 |
Why?
|
| Electrocardiography | 1 | 2020 | 635 | 0.030 |
Why?
|
| Genetic Association Studies | 1 | 2015 | 147 | 0.030 |
Why?
|
| Gene Expression Profiling | 1 | 2016 | 326 | 0.030 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2018 | 370 | 0.030 |
Why?
|
| Registries | 1 | 2016 | 300 | 0.030 |
Why?
|
| Attitude | 1 | 2014 | 41 | 0.030 |
Why?
|
| Patient Preference | 1 | 2014 | 48 | 0.030 |
Why?
|
| Genotype | 1 | 2015 | 742 | 0.030 |
Why?
|
| Patient Care Planning | 1 | 2014 | 58 | 0.030 |
Why?
|
| Health Status | 1 | 2016 | 402 | 0.030 |
Why?
|
| Continuity of Patient Care | 1 | 2014 | 70 | 0.030 |
Why?
|
| Tumor Cells, Cultured | 1 | 2013 | 171 | 0.030 |
Why?
|
| Survival Rate | 1 | 2015 | 894 | 0.030 |
Why?
|
| Patient Readmission | 1 | 2014 | 115 | 0.030 |
Why?
|
| Linear Models | 1 | 2014 | 454 | 0.030 |
Why?
|
| Internet | 1 | 2014 | 203 | 0.030 |
Why?
|
| Depression | 1 | 2016 | 436 | 0.030 |
Why?
|
| Caregivers | 1 | 2013 | 112 | 0.030 |
Why?
|
| Neck Dissection | 1 | 2011 | 9 | 0.030 |
Why?
|
| Hypopharyngeal Neoplasms | 1 | 2011 | 6 | 0.030 |
Why?
|
| Laryngeal Neoplasms | 1 | 2011 | 15 | 0.020 |
Why?
|
| Gastrostomy | 1 | 2011 | 17 | 0.020 |
Why?
|
| Oropharyngeal Neoplasms | 1 | 2011 | 19 | 0.020 |
Why?
|
| Radiotherapy, Adjuvant | 1 | 2011 | 77 | 0.020 |
Why?
|
| Incidence | 1 | 2015 | 1207 | 0.020 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2011 | 191 | 0.020 |
Why?
|
| Recovery of Function | 1 | 2011 | 201 | 0.020 |
Why?
|
| Combined Modality Therapy | 1 | 2011 | 567 | 0.020 |
Why?
|
| Severity of Illness Index | 1 | 2011 | 926 | 0.020 |
Why?
|